Evidence map›Paper›PMID 35603097›Full record

ReviewAnnals of medicine and surgery (2012)2022

BNT162b2 vaccine considerations for immunocompromised individuals: A global perspective.

Hafsa Nazir Jatoi, Samina Abbas, Muhammad Saif Abbasi, Misha Asif Tauni, Shamas Ghazanfar, Mohammad Daniyal Zafar Malick, Muhammad Faiq Umar, Muhammad Junaid Tahir, Muhammad Sohaib Asghar, Ali Ahmed

Open access · diamondAbstract readReview
In one paragraph

Review in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Hafsa Nazir JatoiDow Medical College, Karachi, Pakistan.
Samina AbbasDow Medical College, Karachi, Pakistan.
Muhammad Saif AbbasiDow Medical College, Karachi, Pakistan.
Misha Asif TauniDow Medical College, Karachi, Pakistan.
Shamas GhazanfarDow Medical College, Karachi, Pakistan.
Mohammad Daniyal Zafar MalickDow Medical College, Karachi, Pakistan.
Muhammad Faiq UmarMayo Hospital, Lahore, Pakistan.
Muhammad Junaid TahirLahore General Hospital, Lahore, 54000, Pakistan.
Muhammad Sohaib AsgharDow University of Health Sciences-Ojha Campus, Karachi, Pakistan.
Ali AhmedSchool of Pharmacy, Monash University, Jalan Lagoon Selatan, Bandar Sunway, 47500, Subang Jaya, Selangor, Malaysia.
Dow University of Health Sciences · PKLahore General Hospital · PKMayo Hospital · PKMonash University Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the emergence of COVID-19 vaccines, individuals with comorbidities and immunosuppression require particular attention and should be prioritized for vaccination. However, the majority of vaccine clinical trials excluded people with comorbidities, resulting in a lack of data regarding vaccine efficacy in this demographic. Along with more inclusivity in clinical trials, reaching a definitive conclusion regarding vaccine efficacy in these patients is also crucial. In our review, we highlight the BNT162b2 vaccine safety and efficacy based on the limited number of clinical trials which included this demographic. We also provide vaccine considerations for individuals with cancer, autoimmune diseases, HIV, obesity, diabetes, organ transplant recipients and those undergoing maintenance haemodialysis to help them govern their decision regarding vaccine administration. In conclusion, further studies are required to alleviate any insecurities in patients with comorbidities regarding vaccination and it is recommended that patients are monitored post-vaccination to make sure sufficient immunity is achieved.

Indexed as

ComorbidityCOVID-19InfectionSARS-CoV-2VaccinationVaccine hesitancy

Identifiers

PMID35603097
PMCPMC9110302
OpenAlexW4280612017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.